BR112021017738A2 - - Google Patents

Info

Publication number
BR112021017738A2
BR112021017738A2 BR112021017738A BR112021017738A BR112021017738A2 BR 112021017738 A2 BR112021017738 A2 BR 112021017738A2 BR 112021017738 A BR112021017738 A BR 112021017738A BR 112021017738 A BR112021017738 A BR 112021017738A BR 112021017738 A2 BR112021017738 A2 BR 112021017738A2
Authority
BR
Brazil
Application number
BR112021017738A
Other languages
Portuguese (pt)
Other versions
BR112021017738A8 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR112021017738A2 publication Critical patent/BR112021017738A2/pt
Publication of BR112021017738A8 publication Critical patent/BR112021017738A8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662Stem cells
    • C12N5/0668Mesenchymal stem cells from other natural sources
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/03Compounds acting on the NO pathway, e.g. nitrososarginine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/15Transforming growth factor beta (TGF-β)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • C12N2501/231Interleukin-10 (IL-10)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/11Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112021017738A 2019-03-12 2020-03-12 Células-tronco mesenquimais imunomoduladoras BR112021017738A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19162270 2019-03-12
PCT/EP2020/056625 WO2020182935A1 (en) 2019-03-12 2020-03-12 Immunomodulating mesenchymal stem cells

Publications (2)

Publication Number Publication Date
BR112021017738A2 true BR112021017738A2 (US08124317-20120228-C00009.png) 2021-11-16
BR112021017738A8 BR112021017738A8 (pt) 2022-08-02

Family

ID=65801891

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021017738A BR112021017738A8 (pt) 2019-03-12 2020-03-12 Células-tronco mesenquimais imunomoduladoras

Country Status (9)

Country Link
US (1) US20220154147A1 (US08124317-20120228-C00009.png)
EP (1) EP3938494A1 (US08124317-20120228-C00009.png)
KR (1) KR20210139259A (US08124317-20120228-C00009.png)
CN (1) CN113677789A (US08124317-20120228-C00009.png)
AU (1) AU2020235912A1 (US08124317-20120228-C00009.png)
BR (1) BR112021017738A8 (US08124317-20120228-C00009.png)
CA (1) CA3132414A1 (US08124317-20120228-C00009.png)
MX (1) MX2021010739A (US08124317-20120228-C00009.png)
WO (1) WO2020182935A1 (US08124317-20120228-C00009.png)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202320819A (zh) 2021-07-08 2023-06-01 比利時商比利時百靈佳殷格翰動物醫藥公司 用於治療慢性齦口炎之間葉幹細胞
US20230014549A1 (en) 2021-07-08 2023-01-19 Boehringer Ingelheim Veterinary Medicine Belgium Mesenchymal stem cells for use in the treatment of chronic kidney disease
AU2022307748A1 (en) 2021-07-08 2024-01-25 Boehringer Ingelheim Veterinary Medicine Belgium Mesenchymal stem cells for use in the treatment of osteoarthritis in animals
US20230014698A1 (en) 2021-07-08 2023-01-19 Boehringer Ingelheim Veterinary Medicine Belgium Mesenchymal stem cells for use in the treatment of atopic dermatitis
WO2024033462A1 (en) 2022-08-11 2024-02-15 Boehringer Ingelheim Vetmedica Gmbh Mesenchymal stem cells for use in the treatment of insect-bite hypersensitivity in equines
WO2024133886A1 (en) * 2022-12-23 2024-06-27 Boehringer Ingelheim Veterinary Medicine Belgium Primed mesenchymal stem cells for use in the treatment of chronic kidney disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6328960B1 (en) 1998-03-18 2001-12-11 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
CA2564679C (en) * 2004-03-22 2015-06-23 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
WO2012051210A2 (en) * 2010-10-11 2012-04-19 The Administrators Of The Tulane Educational Fund Mesenchymal stem cells and related therapies
ITRM20110403A1 (it) * 2011-07-28 2013-01-29 Ospedale Pediatrico Bambino Gesu Microvescicole isolate da cellule mesenchimali come agenti immunosoppressori.
WO2017160986A1 (en) 2016-03-16 2017-09-21 Cell Medicine, Inc. Mesenchymal stem cells with enhanced efficacy
WO2020160457A1 (en) * 2019-01-31 2020-08-06 Primegen Biotech, Llc Treatment of atopic dermatitis using mesenchymal stem cells and immune modulation

Also Published As

Publication number Publication date
WO2020182935A1 (en) 2020-09-17
MX2021010739A (es) 2021-12-15
CA3132414A1 (en) 2020-09-17
AU2020235912A1 (en) 2021-10-07
CN113677789A (zh) 2021-11-19
JP2022524764A (ja) 2022-05-10
KR20210139259A (ko) 2021-11-22
US20220154147A1 (en) 2022-05-19
BR112021017738A8 (pt) 2022-08-02
EP3938494A1 (en) 2022-01-19

Similar Documents

Publication Publication Date Title
BR112019017762A2 (US08124317-20120228-C00009.png)
BR112021017339A2 (US08124317-20120228-C00009.png)
BR112021018450A2 (US08124317-20120228-C00009.png)
BR112019016141A2 (US08124317-20120228-C00009.png)
BR112021017939A2 (US08124317-20120228-C00009.png)
BR112021017738A2 (US08124317-20120228-C00009.png)
BR112021017892A2 (US08124317-20120228-C00009.png)
BR112021017782A2 (US08124317-20120228-C00009.png)
AU2020104490A5 (US08124317-20120228-C00009.png)
BR112021017637A2 (US08124317-20120228-C00009.png)
BR112019016142A2 (US08124317-20120228-C00009.png)
BR112019016138A2 (US08124317-20120228-C00009.png)
BR112021018168A2 (US08124317-20120228-C00009.png)
BR112021008711A2 (US08124317-20120228-C00009.png)
BR112021018452A2 (US08124317-20120228-C00009.png)
BR112021017355A2 (US08124317-20120228-C00009.png)
BR112021017703A2 (US08124317-20120228-C00009.png)
BR112021018102A2 (US08124317-20120228-C00009.png)
BR112021018584A2 (US08124317-20120228-C00009.png)
BR112021012348A2 (US08124317-20120228-C00009.png)
BR112021018250A2 (US08124317-20120228-C00009.png)
BR112021018093A2 (US08124317-20120228-C00009.png)
BR112021018084A2 (US08124317-20120228-C00009.png)
BR112021013944A2 (US08124317-20120228-C00009.png)
BR112021013128A2 (US08124317-20120228-C00009.png)

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: BOEHRINGER INGELHEIM VETERINARY MEDICINE BELGIUM (BE)